Literature DB >> 22178231

Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis.

Hung-Yu Lin1, Ming-Chang Yang, Chun-Hsiung Huang, Wen-Jen Wu, Tsan-Jung Yu, For-Wey Lung.   

Abstract

OBJECTIVES: We have reported previously that the TP53 codon72 polymorphism (rs1042522) is associated with the incidence and invasiveness of bladder cancer in a Han Chinese population. Using an enlarged sample, we investigated the role of rs1042522 and of tagSNPs that were predicted to be in linkage disequilibrium with codon72 in relation to the incidence, invasiveness, and prognosis of bladder cancer. METHODS AND MATERIALS: A sample of 201 patients and 311 controls without cancer were genotyped for 5 tagSNPs using tetra-primer ARMS and/or an allele-specific PCR technique.
RESULTS: The genotyped data were analyzed using Haploview 4.2, and a 10,000-permutation test showed that the rs9895829G allele (P = 0.003) and the rs1788227C allele (P = 0.027) were both associated with the incidence of bladder cancer. With respect to haplotype associations, after the data were adjusted for age, the haplotypes GTT (P = 0.001) and GGTC (P < 0.001) were correlated with a low incidence of bladder cancer. In contrast, none of the TP53 haplotypes were associated significantly with high tumor grade or muscle invasiveness. On the basis of Cox regression analysis, haplotype CGCC and invasiveness were associated with cancer-related death. Structural equation modeling showed that haplotypes GGCC and CGCC played opposing roles with respect to bladder cancer-related death; haplotype GGCC was a protective factor, whereas haplotype CGCC was a risk factor.
CONCLUSIONS: The TP53 codon72 polymorphism appears to play a crucial role in determining the association between TP53 haplotype and the incidence and prognosis of bladder cancer. Further functional assays to confirm whether these TP53 haplotypic variants interact with the proteins N-Myc and NDRG is necessary.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Invasiveness; Prognosis; TP53 haplotype; Vulnerability

Mesh:

Substances:

Year:  2011        PMID: 22178231     DOI: 10.1016/j.urolonc.2011.11.031

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Characteristics of Patients With Transitional Cell Carcinoma of the Urinary Bladder in Kermanshah Province, Iran.

Authors:  Mehrdad Payandeh; Masoud Sadeghi; Edris Sadeghi
Journal:  Iran J Cancer Prev       Date:  2015-12-23

2.  TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status.

Authors:  Lei Zhang; Yi Wang; Zhiqiang Qin; Ran Li; Rong Cong; Chengjian Ji; Xianghu Meng; Yamin Wang; Jiadong Xia; Ninghong Song
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

3.  Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population.

Authors:  Mikhlid H Almutairi; Bader O Almutairi; Turki M Alrubie; Sultan N Alharbi; Narasimha R Parine; Abdulwahed F Alrefaei; Ibrahim Aldeailej; Abdullah Alamri; Abdelhabib Semlali
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

4.  Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis.

Authors:  Silvia Pineda; Roger L Milne; M Luz Calle; Nathaniel Rothman; Evangelina López de Maturana; Jesús Herranz; Manolis Kogevinas; Stephen J Chanock; Adonina Tardón; Mirari Márquez; Lin T Guey; Montserrat García-Closas; Josep Lloreta; Erin Baum; Anna González-Neira; Alfredo Carrato; Arcadi Navarro; Debra T Silverman; Francisco X Real; Núria Malats
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

5.  Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer.

Authors:  Nasser Pouladi; Sepehr Abdolahi; Davoud Farajzadeh; Mohammad Ali Hosseinpour Feizi
Journal:  PLoS One       Date:  2019-08-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.